Table 1.
clinical feature of 120 patients in the present study
| Parameter | Age of onset | ||||
|---|---|---|---|---|---|
|
| |||||
| ≤3 mo | 4 to 12 mo | 13 mo to 5 yr | 6 to 12 yr | 13 to 17 yr | |
| Patients with steroid-resistant nephrotic syndrome | |||||
| Patients (n) | 12 | 16 | 50 | 31 | 1 |
| Renal biopsy (n) | (n=1) | (n=7) | (n=32) | (n=30) | IgM nephropathy |
| FSGS:1 | FSGS:5 | FSGS:17 | FSGS:14 | ||
| MCD:1 | MCD:10 | MCD:5 | |||
| IgM nephropathy:1 | MsPGN:3 | MN:5 | |||
| C3 nephropathy:1 | MsPGN:2 | ||||
| IgM nephropathy:1 | sclerosing glomerulonephritis:2 | ||||
| IgA nephropathy:1 | |||||
| MPGN:1 | |||||
| Follow up time, mo | (n=6) | (n=10 ) | (n=45) | (n=30) | |
| 1–204 (median: 39.3) | 1–60 (median: 18.6) | 1–159 (median:37.7) | 1.5–156 (median: 34.3) | 26 | |
| 2 progressed to ESRD and died at the age of 1 yr | 8 progressed to ESRD | 6 progressed to ESRD | increased serum creatine level | ||
| 3 died | 1 had increased serum creatine level | 4 had increased serum creatine level | 7 had increased serum creatine level | ||
| Familial patients, no. (%) | 2 (16.7%) | 0 | 5 (10%) | 5 (16.1%) | 0 |
| Sporadic patients, no. (%) | 10 (83.3%) | 13 (81.2%) | 38 (76%) | 25 (80.6%) | 1 (100%) |
| ND patients, no. (%) | 0 | 3 (18.8%) | 7 (14%) | 1 (3.2%) | 0 |
| Patients with isolated proteinuria | |||||
| Patients (n) | 0 | 2 | 4 | 3 | 1 |
| Renal biopsy (n) | 0 | (n=2 ) | (n=2 ) | (n=3 ) | MsPGN |
| FSGS:2 | sclerosing glomerulonephritis:1 MsPGN:1 |
FSGS:3 | |||
| Follow up time, mo | 0 | (n=2 ) | (n=4) | (n=3) | (n=1) |
| 4, 28 | 5, 23, 48, 48 | 1, 12, 72 | 18 | ||
| Normal renal function | 1 died | Normal renal function | Normal renal function | ||
| Familial patients, no. (%) | 0 | 1 (50%) | 4 (100%) | 1 (33.3%) | 1 (100%) |
| Sporadic patients, no. (%) | 0 | 0 | 0 | 2 (66.7%) | 0 |
| ND patients, no. (%) | 0 | 1 (50%) | 0 | 0 | 0 |
mo, month; yr, year; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; MsPGN: mesangioproliferative glomerulonephritis; MN: membranous glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; ESRD, end stage renal disease; Familial, a positive family history with proteinuria and/or renal failure; Sporadic, a negative family history with proteinuria and/or renal failure; ND, no data of a family history.